We’ve developed a unique technology to produce commercial grade, sustained-release microparticulate protein therapeutics suitable for oral and mucosal delivery.
We aggressively file new patent applications to protect our technology, inventions, and improvements.
TheraPYX has teamed with Intravacc to develop the world’s first prophylactic vaccine against gonorrhea.
TheraPYX has revolutionized the treatment of inflammatory diseases by innovating a new type of oral protein therapeutic.
We're changing the future of pharmaceuticals. Learn more about the company behind the innovation.
Interested? Let’s change the future of pharmaceuticals together.Contact Us